Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization

Biomaterials

Volumn 32, Issue 10, 2011, Pages 2662-2672

  Xue, Hui Yi ^a   Wong, Ho Lun ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

Cancer chemotherapy; Chemosensitization; Drug delivery; Lipid nanoparticles; Small interfering RNA; Survivin

Indexed keywords

CANCER CHEMOTHERAPY; CHEMOSENSITIZATION; LIPID NANOPARTICLES; SMALL-INTERFERING RNA; SURVIVIN;

CHEMOTHERAPY; DISEASE CONTROL; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; GENE THERAPY; NANOPARTICLES;

RNA;

DOCETAXEL; LYSOSOME ENZYME; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CHEMOSENSITIZATION; DOSE RESPONSE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RNA INTERFERENCE; TIMED DRUG RELEASE;

CELL LINE, TUMOR; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SPACE; KINETICS; LIPIDS; MICROSCOPY, FLUORESCENCE; NANOSTRUCTURES; NANOTECHNOLOGY; PARTICLE SIZE; RNA INTERFERENCE; RNA, SMALL INTERFERING; STATIC ELECTRICITY; STEROL ESTERASE; TAXOIDS; TIME FACTORS;

EID: 79251594675     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.12.029     Document Type: Article

References (41)

1. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007, 59:75-86.
2. Kumar L.D., Clarke A.R. Gene manipulation through the use of small interfering RNA (siRNA): from in vitro to in vivo applications. Adv Drug Deliv Rev 2007, 59:87-100.
3. Pirollo K.F., Chang E.H. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res 2008, 68:1247-1250.
4. Raemdonck K., Vandenbroucke R.E., Demeester J., Sanders N.N., De Smedt S.C. Maintaining the silence: reflections on long-term RNAi. Drug Discov Today 2008, 13:917-931.
5. Bartlett D.W., Davis M.E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 2006, 34:322-333.
6. Tannock I.F., de Wit R., Berry W., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus predisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
7. Goodin S., Rao K.V., Kane M., Dave N., Capanna T., Doyle-Lindrud S., et al. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2005, 56:199-204.
8. Gary D.J., Puri N., Won Y.Y. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 2007, 121:64-73.
9. Audouy S., Hoekstra D. Cationic lipid-mediated transfection in vitro and in vivo. Mol Membr Biol 2001, 18:129-143.
10. Snove O., Rossi J.J. Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi. Genome Biol 2006, 7:231.
11. Judge A., MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 2008, 19:111-124.
12. Kim S.H., Jeong J.H., Kim T.I., Kim S.W., Bull D.A. VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine). Mol Pharm 2009, 6:718-726.
13. Kawata E., Ashihara E., Kimura S., Takenaka K., Sato K., Tanaka R., et al. Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol Cancer Ther 2008, 7:2904-2912.
14. Han H.D., Mangala L.S., Lee J.W., Shahzad M.M., Kim H.S., Shen D., et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 2010, 16:3910-3922.
15. Halder J., Kamat A.A., Landen C.N., Han L.Y., Lutgendorf S.K., Lin Y.G., et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006, 12:4916-4924.
16. Choi Y.S., Lee J.Y., Suh J.S., Kwon Y.M., Lee S.J., Chung J.K., et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 2010, 31:1429-1443.
17. Peer D., Zhu P., Carman C.V., Lieberman J., Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A 2007, 104:4095-4100.
18. Ladewig K., Niebert M., Xu Z.P., Gray P.P., Lu G.Q. Efficient siRNA delivery to mammalian cells using layered double hydroxide nanoparticles. Biomaterials 2010, 31:1821-1829.
19. Kirkland-York S., Zhang Y., Smith A.E., York A.W., Huang F., McCormick C.L. Tailored design of Au nanoparticle-siRNA carriers utilizing reversible addition-fragmentation chain transfer polymers. Biomacromolecules 2010, 11:1052-1059.
20. Muller R.H., Karsten M., Sven G. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000, 50:161-177.
21. Wong H.L., Bendayan R., Rauth A.M., Li Y., Wu X.Y. Chemotherapy with anticancer drugs entrapped into solid lipid nanoparticles. Adv Drug Deliv Rev 2007, 59:491-504.
22. Muller R.H., Radtke M., Wissing S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002, 242:121-128.
23. Wong H.L., Rauth A.M., Bendayan R., Wu X.Y. Combinational treatment with doxorubicin and GG918 (Elacridar) using polymer-lipid hybrid nanoparticles (PLN) and evaluation of strategies for multidrug-resistance reversal in human breast cancer cells. J Control Release 2006, 116:275-284.
24. Wong H.L., Bendayan R., Rauth A.M., Wu X.Y. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 2004, 93:1993-2008.
25. Pennati M., Folini M., Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007, 28:1133-1139.
26. Nakahara T., Takeuchi M., Kinoyama I., Minematsu T., Shirasuna K., Matsuhisa A., et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007, 67:8014-8021.
27. Rahman K.M.W., Banerjee S., Ali S., Ahmad A., Wang Z., Kong D., et al. 3,3'-diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res 2009, 69:4468-4475.
28. Raj D., Liu T., Samadashwily G., Li F., Grossman D. Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 2008, 29:194-201.
29. MacDonald R.C., MacDonald R.I., Menco B.P., Takeshita K., Subbarao N.K., Hu L.R. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta 1991, 1061:297-303.
30. Olbrich C., Kayser O., Muller R.H. Lipase degradation of Dynasan 114 and 116 solid-lipid nanoparticles (SLN)-effect of surfactants, storage time and crystallinity. Int J Pharm 2002, 237:119-128.
31. Wang W., Li W., Ikeda Y., Miyagawa J.I., Taniguchi K., Miyoshi E., et al. Ectopic expression of 1,6 fucosyltransferase in mice causes steatosis in the liver and kidney accompanied by a modification of lysosomal acid lipase. Glycobiology 2001, 11:165-174.
32. Nilsson-Ehle P., Garfinkel A.S., Schotz M.C. Lipolytic enzymes and plasma lipoprotein metabolism. Annu Rev Biochem 1980, 49:667-693.
33. Li Y., Kucuk O., Hussain M., Abrams J., Cher M.L., Sarkar F.H. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 2006, 66:4816-4825.
34. Wang M.T., Jin Y., Yang Y.X., Zhao C.Y., Yang H.Y., Xu X.F., et al. In vivo biodistribution, anti-inflammatory, and hepatoprotective effects of liver targeting dexamethasone acetate loaded nanostructured lipid carrier system. Int J Nanomedicine 2010, 5:487-497.
35. Xu Z.P., Niebert M., Porazik K., Walker T.L., Cooper H.M., Middelberg A.P. Subcellular compartment targeting of layered double hydroxide nanoparticles. J Control Release 2008, 130:86-94.
36. Chattopadhyay N., Zastre J., Wong H.L., Wu X.Y., Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, Atazanavir, By a human brain endothelial cell line. Pharm Res 2008, 25:2262-2271.
37. Hanafy A., Spahn-Langguth H., Vergnault G., Grenier P., Tubic Grozdanis M., Lenhardt T., et al. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev 2007, 59:419-426.
38. Amyere M., Mettlen M., van der Smissen P., Platek A., Payrastre B., Veithen A., et al. Origin, originality, functions, subversions and molecular signaling of macropinocytosis. Int J Med Microbiol 2002, 291:487-494.
39. Wong H.L., Bendayan R., Rauth A.M., Xue H.Y., Babakhanian K., Wu X.Y. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle (PLN) system. J Pharmacol Exp Ther 2006, 317:1372-1381.
40. Clarke S.J., Rivory L.P. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999, 36:99-114.
41. Patterson S.G., Wei S., Chen X., Sallman D.A., Gilvary D.L., Zhong B., et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006, 25:6113-6122.